Haleon (HLN) Return on Assets (2023 - 2025)

Haleon (HLN) posted Return on Assets of 0.0% for Q4 2025, down 27.7% on a QoQ basis from 0.0% in Q4 2024, and little changed year-over-year from 0.0% in Q4 2024.

Haleon (HLN) Return on Assets (2023 - 2025) Analysis & Trends

Haleon's Return on Assets history runs 3 years deep, the most recent figure standing at 0.0% for Q4 2025.

  • Quarterly Return on Assets changed 0.0% year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
  • Return on Assets was 0.0% for Q4 2025 at Haleon, down from 0.0% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.0% in Q4 2023 and bottomed at 0.0% in Q4 2025.
  • A 3-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Assets.
  • Peak annual rise in Return on Assets reached 0 bps in 2024, while the deepest fall reached 0 bps in 2024.
  • Haleon's Return on Assets stood at 0.0% in 2023, then tumbled by 46 bps to 0.0% in 2024, then fell by 28 bps to 0.0% in 2025.
  • Business Quant data shows HLN's Return on Assets at 0.0% in Q4 2025, 0.0% in Q4 2024, and 0.0% in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - 0.00%
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 0.00%
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 0.00%
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 0.00%
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 0.00%
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 0.00%
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 0.00%
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 0.00%
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn 0.00%

Historic Data

Download Data
DateValue
Dec 31, 2025 0.00%
Dec 31, 2024 0.00%
Jun 30, 2024 0.00%
Dec 31, 2023 0.00%